MYRIAM
ABURTO BARRENECHEA
Publicaciones (40) Publicaciones de MYRIAM ABURTO BARRENECHEA
2024
-
Influence of physical activity on the prognosis of COPD patients: the HADO.2 score – health, activity, dyspnoea and obstruction
ERJ Open Research, Vol. 10, Núm. 1
2023
-
Change in physical activity related to admission for exacerbation in COPD patients
Respiratory Medicine, Vol. 212
-
Impact of COVID-19 Infection on Patients with Preexisting Interstitial Lung Disease: A Spanish Multicentre Study
Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 273-276
-
Screening criteria for interstitial lung disease associated to rheumatoid arthritis: Expert proposal based on Delphi methodology
Reumatologia Clinica, Vol. 19, Núm. 2, pp. 74-81
2022
-
Changes in health-related quality of life as a marker in the prognosis in COPD patients
ERJ Open Research, Vol. 8, Núm. 1
-
Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity
Archivos de Bronconeumologia, Vol. 58, Núm. 2, pp. 135-141
-
SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosis
Reumatologia Clinica, Vol. 18, Núm. 8, pp. 443-452
-
SER-SEPAR recommendations for the the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment
Reumatologia Clinica, Vol. 18, Núm. 9, pp. 501-512
-
Screening of interstitial lung disease in patients with rheumatoid arthritis: A systematic review
Reumatologia Clinica, Vol. 18, Núm. 10, pp. 587-596
2021
-
Checking Siblings of Patients with Idiopathic Pulmonary Fibrosis as a Scheme for Early Disease Detection
Annals of the American Thoracic Society
2020
-
Complications and hospital admission in the following 90 days after lung cryobiopsy performed in interstitial lung disease
Respiratory Medicine, Vol. 165
-
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
The Lancet Respiratory Medicine, Vol. 8, Núm. 5, pp. 453-460
-
Predictive factors over time of health-related quality of life in COPD patients
Respiratory research, Vol. 21, Núm. 1, pp. 138
2019
-
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study
The Lancet Respiratory Medicine, Vol. 7, Núm. 9, pp. 771-779
-
COPD classification models and mortality prediction capacity
International Journal of COPD, Vol. 14, pp. 605-613
2018
-
Diagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis
Medical sciences (Basel, Switzerland), Vol. 6, Núm. 3
-
Importance of early diagnosis and treatment in idiopathic pulmonary fibrosis
Expert Review of Respiratory Medicine
2016
-
Chronic obstructive pulmonary disease subtypes. transitions over time
PLoS ONE, Vol. 11, Núm. 9
-
Noninvasive ventilation for severely acidotic patients in respiratory intermediate care units: Precision medicine in intermediate care units
BMC Pulmonary Medicine, Vol. 16, Núm. 1
-
Outcomes of a telemonitoring-based program (telEPOC) in frequently hospitalized COPD patients
International Journal of COPD, Vol. 11, Núm. 1, pp. 2919-2930